Answers are grounded in this paper and cite their sources.
Nisha–Amalaki (NA), an Ayurvedic formulation of Curcuma longa ( Nisha ) and Emblica officinalis ( Amalaki ), is traditionally used for glycemic control and antioxidant support. Since diabetes mellitus (DM) and pancreatic cancer (PC) share metabolic-inflammatory mechanisms, this study employed integrative computational approaches to identify NA phytochemicals and their putative molecular targets mediating dual antidiabetic and anticancer effects. NA phytochemicals were retrieved from databases and literature, filtered through ADMET and drug-likeness criteria, and mapped to DM- and PC-related genes. From 311 reported NA phytochemicals, curcumin (an.), divanillalaceton, and caffeic acid emerged as principal phytochemicals. Enrichment analysis implicated IL-6/JAK/STAT3, apical junction, and apoptosis pathways. Box plot analysis showed all 14 hub genes were upregulated in PC tissues, while high EGFR and MMP1 expression correlated with poorer survival. Among the 14 hub genes, eight key genes were further refined by topology algorithms, that is, APP , TLR4 , NOS2 , EGFR , MMP9 , STAT3 , NFE2L2 , and ALOX5 . Cytotoxicity predictions suggested potential antiproliferative activity of the phytochemicals against multiple PC cell lines. Molecular docking and dynamics indicated thermodynamically stable phytochemical–target interactions, with curcumin (an.) showing stronger EGFR binding than gefitinib. This study provides computational evidence supporting NA’s potential in treating PC and DM; probably via modulating inflammatory, metabolic, and junctional pathways.
No takes yet. Share an insight, caveat, or question.
Sivakumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: